Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Gene Therapy to Target CD22 for Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma by Suzhou Fundamenta Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Gene Therapy to Target CD22 for Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma is under clinical development by Suzhou Fundamenta Therapeutics...